Sandbox/MS: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:
|C03=<div style="float: left; text-align: center; width:15em">'''Stage C''' </div>
|C03=<div style="float: left; text-align: center; width:15em">'''Stage C''' </div>
|C04=<div style="float: left; text-align: center; width:15em">'''Stage D'''</div>}}
|C04=<div style="float: left; text-align: center; width:15em">'''Stage D'''</div>}}
{{family tree | |`|-|v|-|'| | |!| | | | | | | | }}
{{family tree | |`|-|v|-|'| | |!| | | | |!| | | }}
{{family tree | | | B01 | | | B02 | | | | | | |B01=<div style="float: left; text-align: left; width:15em">❑ Yearly follow up is recommended with history and physical examination in asymptomatic patients with mild [[MS]] <br>❑ For mild [[MS]] repeat [[echocardiography]] every 3-5 years <br> ❑ For moderate [[MS]] repeat [[echocardiography]] every 1-2 years <br> ❑ The onset of symptoms require medical therapy and re-evaluation of the stage as the patient may also need intervention in moderate and severe disease</div>|B02=<div style="float: left; text-align: left; width:15em"> '''[[Mitral stenosis resident survival guide#Summary for mitral stenosis intervention|Continue with the summary for mitral stenosis intervention below]]'''</div>}}
{{family tree | | | B01 | | | B02 | | | |!| | |B01=<div style="float: left; text-align: left; width:15em">❑ Yearly follow up is recommended with history and physical examination in asymptomatic patients with mild [[MS]] <br>❑ For mild [[MS]] repeat [[echocardiography]] every 3-5 years<ref name="guidelines 2008">{{Cite web  | last =  | first =  | title = 2008 Focused update incorporated into the ACC/AH... [Circulation. 2008] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=18820172 | publisher =  | date =  | accessdate = }}</ref> <br> ❑ For moderate [[MS]] repeat [[echocardiography]] every 1-2 years<ref name="guidelines 2008">{{Cite web  | last =  | first =  | title = 2008 Focused update incorporated into the ACC/AH... [Circulation. 2008] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=18820172 | publisher =  | date =  | accessdate = }}</ref> <br> ❑ The onset of symptoms require medical therapy and re-evaluation of the stage as the patient may also need intervention in moderate and severe disease</div>|B02=<div style="float: left; text-align: left; width:15em"> '''[[Mitral stenosis resident survival guide#Summary for mitral stenosis intervention|Continue with the summary for mitral stenosis intervention below]]'''</div>}}
{{family tree | | | | | |!| | | | | | | | | | | }}
{{family tree | | | | | | | | | | | | | B03 | | |B03=<div style="float: left; text-align: left; width:15em">'''''The presence of symptoms is an indication for intervention''''' <br>
{{family tree | | | | | |!| | | | | | | | | | | }}
'''Indications for pharmacotherapy:''' <br> ❑ Alleviate symptoms before surgery <br> ❑ Control symptoms precipitated by intercurrent illness or during pregnancy <br> ❑ Persistent symptoms after intervention <br> '''Medications:''' <br> ❑ [[Diuretics]]: used to relieve symptoms of pulmonary vascular congestion (shortness of breath, [[orthopnea]] and [[paroxysmal nocturnal dyspnea]]) and in case of right sided [[heart failure]] <br> ❑ [[Beta blockers]]: useful to control exertional symptoms as it decreases [[heart rate]] and [[cardiac output]] during exercise, thus decreasing the rise in transmitral gradient <br> ❑ [[Digoxin]]: used in case of right or left ventricular systolic dysfunction and also during [[atrial fibrillation]] (not the first line) <br> ❑ [[Statin]] therapy: slower progression of rheumatic [[mitral stenosis]]<ref name="www.ncbi.nlm.nih.gov">{{Cite web  | last =  | first =  | title = Effect of hydroxymethylglutaryl coenzyme-a reduc... [Circulation. 2010] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=20439789 | publisher =  | date =  | accessdate = }}</ref>
{{family tree | | | | | |!| | | | | | | | | | | }}
<br>
{{family tree | | | | | |!| | | | | | | | | | | }}
'''Antithrombotic recommendations:''' <br> Consider [[anticoagulation therapy]] in [[MS]] patients with: <br> ❑ [[AF]] <br> ❑ Prior embolic event <br> ❑ Left atrial thrombus <br> '''''Long term oral anticoagulation (2.0-3.0 INR)'''''
{{family tree | | | | | |!| | | | | | | | | | | }}
<br>
{{family tree | | | | | |!| | | | | | | | | | | }}
'''Prevention of endocarditits:''' <br> No longer require antimicrobial prophylaxis </div>}}
{{family tree | | | | | | | | | | | | | |!| | | }}
{{family tree | | | | | | | | | | | | | A01 | |A01=<div style="float: left; text-align: left; width:15em"> '''[[Mitral stenosis resident survival guide#Summary for mitral stenosis intervention|Continue with the summary for mitral stenosis intervention below]]'''</div> }}    
{{family tree | | | | | | | | | | | | | | | | | }}
{{familytree/end}}
{{familytree/end}}



Revision as of 19:07, 29 April 2014

 
 
 
 
Classify mitral stenosis based on TTE:
❑ Valve anatomy
❑ Valve hemodynamics gradient
❑ Hemodynamic consequences
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage A
 
Stage B
 
Stage C
 
Stage D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Yearly follow up is recommended with history and physical examination in asymptomatic patients with mild MS
❑ For mild MS repeat echocardiography every 3-5 years[1]
❑ For moderate MS repeat echocardiography every 1-2 years[1]
❑ The onset of symptoms require medical therapy and re-evaluation of the stage as the patient may also need intervention in moderate and severe disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The presence of symptoms is an indication for intervention

Indications for pharmacotherapy:
❑ Alleviate symptoms before surgery
❑ Control symptoms precipitated by intercurrent illness or during pregnancy
❑ Persistent symptoms after intervention
Medications:
Diuretics: used to relieve symptoms of pulmonary vascular congestion (shortness of breath, orthopnea and paroxysmal nocturnal dyspnea) and in case of right sided heart failure
Beta blockers: useful to control exertional symptoms as it decreases heart rate and cardiac output during exercise, thus decreasing the rise in transmitral gradient
Digoxin: used in case of right or left ventricular systolic dysfunction and also during atrial fibrillation (not the first line)
Statin therapy: slower progression of rheumatic mitral stenosis[2]
Antithrombotic recommendations:
Consider anticoagulation therapy in MS patients with:
AF
❑ Prior embolic event
❑ Left atrial thrombus
Long term oral anticoagulation (2.0-3.0 INR)

Prevention of endocarditits:
No longer require antimicrobial prophylaxis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classify mitral stenosis based on the following findings on TTE:
❑ Valve anatomy
❑ Valve hemodynamics gradient
❑ Hemodynamic consequences
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage A

❑ Patient at risk of developing mitral stenosis
❑ Mild valve doming during diastole
❑ Normal transmitral flow velocity
 
Stage B

❑ Progressive mitral stenosis
❑ Valve area > 1.5 cm²
❑ Rheumatic valve changes with commissural fusion and diastolic doming of the mitral valve leaflets
❑ Increased transmitral flow velocities
❑ Diastolic pressure half-time < 150 ms ❑ Mild to moderate left atrial enlargement
❑ Normal pulmonary pressure at rest
 
Stage C

❑ Asymptomatic severe mitral stenosis
❑ Valve area ≤ 1.5 cm² (≤ 1 cm² in severe mitral stenosis)
❑ Rheumatic valve changes with commissural fusion and diastolic doming of the mitral valve leaflets
❑ Diastolic pressure half-time ≥ 150 ms (≥ 220 ms with very severe mitral stenosis)
❑ Elevated pulmonary artery systolic pressure > 30 mmHg
❑ Severe left atrial enlargement
 
Stage D

❑ Symptomatic severe mitral stenosis
❑ Valve area ≤ 1.5 cm² (≤ 1 cm² in severe mitral stenosis)
❑ Rheumatic valve changes with commissural fusion and diastolic doming of the mitral valve leaflets
❑ Diastolic pressure half-time ≥ 150 ms (≥ 220 ms with very severe mitral stenosis)
❑ Elevated pulmonary artery systolic pressure > 30 mmHg
❑ Severe left atrial enlargement
 
 
 
 


 
 
 
 
 
 
Identify cardinal findings that increase the pretest probability of mitral stenosis

Mid diastolic murmur
❑ Low-pitched diastolic rumble
❑ Associated with an opening snap
❑ Best heard at the cardiac apex
❑ Radiating to the axilla
❑ Increases with lying down, raising the legs and with exercise
❑ Decreases with valsalva maneuver and amyl nitrate
❑ Reduced pulse pressure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any of the following findings of decompensated mitral stenosis that require urgent management?
Tachycardia
Hypotension
Severe dyspnea
Loss of consciousness
Chest pain
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What is the complication of mitral stenosis that is causing decompensation?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ Suspect in case of:
❑ Sudden weakness or paralysis - face, arm or leg
❑ Speech or visual difficulties
Altered level of consciousness
❑ Sudden severe headache
 

❑ Suspect in case of palpitations
❑ Order an ECG immediately looking for
❑ Irregularly irregular rhythm, and
❑ Absent P waves
 

❑ Suspect in case of:
❑ Acute onset of exertional dyspnea or dyspnea at rest
❑ Pleuritic or substernal chest pain
Hemoptysis
 

❑ Suspect in case of severe dyspnea
❑ Increased jugular venous pressure immediately

Hepatomegaly ± pulsatile liver

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1. 1.0 1.1 "2008 Focused update incorporated into the ACC/AH... [Circulation. 2008] - PubMed - NCBI".
  2. "Effect of hydroxymethylglutaryl coenzyme-a reduc... [Circulation. 2010] - PubMed - NCBI".